RCT 1100
Alternative Names: RCT-1100Latest Information Update: 03 Jul 2024
At a glance
- Originator ReCode Therapeutics
- Class Gene therapies; RNA
- Mechanism of Action DNAI1 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Primary ciliary dyskinesia
Most Recent Events
- 27 Jun 2024 RCT 1100 receives Orphan Drug status for Primary ciliary dyskinesia in USA
- 03 Jan 2024 Adverse events data from a phase I trial in Primary ciliary dyskinesia released by ReCode Therapeutics
- 28 Feb 2023 ReCode Therapeutics plans a phase Ib trial for Primary ciliary dyskinesia (Inhalation, Aersol) in Q3 of 2023